Evidence for a Functional Interaction between the ClC-2 Chloride Channel and the Retrograde Motor Dynein Complex*

Sonja U. DhaniDagger §, Raha Mohammad-Panah, Najma Ahmed, Cameron Ackerley||, Mohabir Ramjeesingh, and Christine E. BearDagger **

From the  Programme in Structural Biology, Research Institute, Hospital for Sick Children, Toronto, Ontario M5G 2X8, and Departments of Dagger  Physiology and || Pathology, University of Toronto, Toronto, Ontario M5S 1A8, Canada

Received for publication, September 25, 2002, and in revised form, February 21, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The ClC-2 chloride channel has been implicated in essential physiological functions. Analyses of ClC-2 knock-out mice suggest that ClC-2 expression in retinal pigment epithelia and Sertoli cells normally supports the viability of photoreceptor cells and male germ cells, respectively. Further, other studies suggest that ClC-2 expression in neurons may modify inhibitory synaptic transmission via the gamma -aminobutyric acid, type A receptor. However, complete understanding of the physiological functions of ClC-2 requires elucidation of the molecular basis for its regulation. Using cell imaging and biochemical and electrophysiological techniques, we show that expression of ClC-2 at the cell surface may be regulated via an interaction with the dynein motor complex. Mass spectrometry and Western blot analysis of eluate from a ClC-2 affinity matrix showed that heavy and intermediate chains of dynein bind ClC-2 in vitro. The dynein intermediate chain co-immunoprecipitates with ClC-2 from hippocampal membranes suggesting that they also interact in vivo. Disruption of dynein motor function perturbs ClC-2 localization and increases the functional expression of ClC-2 in the plasma membranes of COS7 cells. Thus, cell surface expression of ClC-2 may be regulated by dynein motor activity. This work is the first to demonstrate an in vivo interaction between an ion channel and the dynein motor complex.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

ClC-2 is a member of the ClC family of chloride channels (1). Expression of recombinant ClC-2 in Xenopus oocytes (2) and in mammalian cells (3) confers the expression of a hyperpolarization and swelling-activated chloride conductance path exhibiting an inwardly rectifying current-voltage relationship. Recent studies in which ClC-2 expression was disrupted in model organisms support the claim that ClC-2 directly mediates this chloride conductance. For example, a chloride conductance path with the above biophysical properties was detected in studies of salivary gland cells obtained from normal mice whereas this function was absent in salivary gland cells obtained from ClC-2 knock-out mice (4). Similarly, depletion of the Caenorhabditis elegans ortholog of ClC-2, CLH-3, in maturing oocytes by RNA interference leads to the complete abrogation of the native, inwardly rectifying chloride conductance (5).

The physiological consequences of disrupting ClC-2 expression in these organisms implicate a role for this channel at the cell surface in modifying extracellular microenvironments or cell-cell communication (5, 6). For example, ClC-2-deficient mice are blind, and the males are infertile. These defects have been attributed to altered chloride conductance across the plasma membrane of retinal pigment epithelium and Sertoli cells, affecting the microenvironment surrounding photoreceptors and male germ cells, respectively. Localization of ClC-2 to the apical membrane of fetal lung epithelia suggests a role in regulating airway surface fluid (7, 8). In addition, ClC-2 channel function has been implicated in mediating intestinal fluid secretion, as it has been localized close to the apical tight junctions of intestinal epithelia (9, 10).

Detailed studies have revealed that ClC-2 channels are also localized to intracellular vesicular compartments. Electron micrographs of immunogold-labeled ClC-2 endogenously expressed in hippocampal neurons show that it is localized not only to the plasma membrane of somata, proximal dendrites, axon initial segments but also to small transport vesicles in the cytosol (11). This expression pattern is similar to that described previously for the gamma -aminobutyric acid, type A receptor and suggests that, as in the case of the gamma -aminobutyric acid, type A receptor, the number of ClC-2 channels on the cell surface may be regulated by vesicular transport. In fact, recent studies by Bali et al. (12) showed that inhibitors of phosphatidylinositol 3-kinase, a lipid kinase with a well established role in membrane trafficking, reduce the basal amplitude of ClC-2-mediated chloride currents measured by patch clamp electrophysiology on the cell surface (12). These findings suggest that cell surface expression of ClC-2 may be regulated via membrane trafficking. However, as yet, little is known regarding the molecular components that regulate the cell surface expression of ClC-2.

In the present study, using an integrated approach involving biochemical and cell imaging and electrophysiological techniques, we show that ClC-2 interacts with the retrograde dynein motor complex in vitro and in vivo. Further, this interaction likely mediates trafficking of ClC-2 as the subcellular distribution and functional expression of this channel at the cell surface is disrupted by inhibition of dynein function. To our knowledge, these are the first results to demonstrate an in vivo interaction between an ion channel and the dynein motor complex.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Constructs and Antibodies-- The antisense ClC-2 construct was made by cloning the rat ClC-2 open reading frame into pCDNA 3.1(-) vector so that the reversed restriction sites on this vector would reverse the orientation of the open reading frame to create the antisense plasmid (10). The constructs for the expression of GFP1-tagged dynamitin, and DSRed-tagged CC1 were kindly provided by Dr. T. Schroer (The Johns Hopkins University). For immunofluorescence analysis, endogenous ClC-2 was detected using a peptide-purified polyclonal antibody (8 µg/ml) directed against the N terminus of ClC-2. Dynein complex was labeled with a monoclonal antibody against the intermediate chain (IC) of dynein (1:100; Chemicon, Pittsburgh, PA), early endosomal compartments with monoclonal anti-EEA1 antibody (1:200; BD Biosciences), and tubulin with monoclonal anti-alpha tubulin (1:2000; Sigma). Fluorescein-conjugated donkey anti-mouse IgG (in 50% glycerol; 1:250; Jackson ImmunoResearch Laboratories) and donkey anti-rabbit IgG (1:1000; Molecular Probes, Eugene, OR) secondary antibodies were used. For immunogold labeling, goat anti-rabbit IgG 10-nm gold complexes and goat anti-mouse IgG 5-nm gold complexes (Amersham Biosciences) were used.

Several antibodies were screened for the detection of endogenous dynein: two monoclonal antibodies against the dynein heavy chain (DHC) and intermediate chain (DIC) subunits, respectively (Sigma), and one against the intermediate chain (Chemicon). However, only the Chemicon antibody exhibited positive immunoreactivity upon analysis of rat hippocampal homogenate (anti-dynein IC; 1:1,000; Chemicon). Endogenous ClC-2 was detected using polyclonal antibodies raised against either the N or the C terminus of ClC-2 (directed against residues 31-74 and 869-907 of rat ClC-2, respectively). Where relevant, actin detection with a monoclonal actin antibody (1:1,000; Sigma) was used as a control for equal protein loading.

Cell Culture-- COS7 cells (obtained from the American Type Culture Collection, Manassas, VA) were cultured at 37 °C in minimum essential medium (Wisent Inc., Montreal, Canada) supplemented with 10% fetal calf serum. Cells were generally grown to 30% confluency prior to transfection, as well as for patch clamp experiments. Transfections were performed on cells (seeded onto 35-mm coverslips 12 h prior to transfection) with SuperFect transfection reagent (Qiagen, Chatsworth, CA). Cells were incubated with transfection reagent for 3-6 h in 5% serum-supplemented medium, washed with phosphate-buffered saline (PBS; Wisent Inc.), and grown for 16-24 h.

For nocodazole experiments, cells were washed three times with PBS, followed by a 30-min incubation with 35 µM nocodazole (methyl-(5-2-thienylcarbonyl)-1H-benzimidazol-2-yl)carbamate; Sigma) in serum-free medium, at either 4 or 37 °C. For experiments requiring drug recovery, cells were washed extensively with PBS following exposure to nocodazole and incubated with serum-supplemented medium for 120 min. In cycloheximide treatment experiments, cells were washed three times in PBS and then incubated with growth medium supplemented with 100 µg/ml cycloheximide (Sigma) for 4 h to arrest protein synthesis.

Immunofluorescence and Confocal Microscopy-- For immunofluorescence experiments, cells were washed with PBS followed by fixation with 4% paraformaldehyde in PBS for 20 min at room temperature. Cells were permeabilized for 10 min with 0.1% Triton in PBS. Coverslips were blocked in 5% goat serum (Vector Laboratories, Burlingame, CA) in PBS for 2 h followed by a 1-h incubation in primary antibody diluted to the desired concentration in blocking buffer. Coverslips were washed in blocking buffer for 30 min before incubation in secondary antibody for 1 h and washed again in PBS before mounting with DAKO (DAKO, Copenhagen, Denmark) medium. For double-labeling experiments, two primary antibodies developed in different species were applied together, followed by simultaneous detection using Cy3 and fluorescein isothiocyanate-coupled secondary antibodies. Slides were analyzed with a Carl Zeiss confocal laser microscope (LSM 510) under a ×63 objective. Optical sections were generally 0.7-0.9 µm thick.

Image Analysis-- The extent of co-localization of ClC-2 with EEA1 was quantified using a modification of methods described previously (44, 45). Briefly, background-corrected EEA1-specific immunofluorescence was subtracted from ClC-2-specific immunofluorescence to yield a "difference" image (using Scion Image; Scion Corporation). Vesicular structures within this difference image represent ClC-2 and EEA1 co-localized within endosomes. The extent of co-localization of ClC-2 with EEA1 was determined as the percent intensity of the co-localized signal relative to the total ClC-2-specific immunofluorescence.

ImageJ (NIH imaging) was employed for line scanning analysis to quantitatively assess ClC-2 subcellular distribution in COS7 cells. Lines were typically drawn from the periphery of the nucleus to the cell edge through the intracellular staining pattern for ClC-2. This line was then divided into four equal segments. The fluorescence intensity for each segment was quantified and expressed as a fraction of total fluorescence intensity.

Immunogold Electron Microscopy-- Paraformaldehyde- and glutaraldehyde-fixed COS7 cells were infused with a solution of 10% gelatin in PBS at 37 °C, allowed to gel at 4 °C, and infused with 2.3 M sucrose overnight. Ultrathin sections (100 nm) were mounted on Formvar-coated nickel grids. Sections were labeled with ClC-2 and/or dynein antibodies as described previously (9). Controls included the omission of either of the primary antisera. Specimens were examined and images acquired with a JEOL JEM transmission electron microscope (JEOL USA, Peabody, MA) equipped with a digital camera (AMT Corp., Danvers, MA).

Protein Affinity Columns and Immunoblotting-- 1 ml Hi-Trap columns (Amersham Biosciences) were injected with either 10 mg/ml amylase (Sigma) or ClC-2, purified as described previously (14) in 0.2 M NaHCO3, 0.5 M NaCl, pH 8.3 (supplemented with 4% pentadecafluorooctanoic acid (Dakwood Products Inc., West Columbia, SC) for the application of purified ClC-2). After a 30-min incubation at room temperature, the column was washed with Buffer A (0.5 M ethanolamine, 0.5 M NaCl, pH 8.3), followed by Buffer B (0.1 M acetate, 0.5 M NaCl, pH 4.0). Mouse brain lysate was passed through the column, equilibrated previously with 1% Triton in PBS, pH 8.0. Briefly, tissue was homogenized in 0.1% Triton X-100 in PBS with protease inhibitors, 10 mg/ml aprotinin and leupeptin, 1 mM benzamidine, 2 mM dithiothreitol, 10 µM E64, 0.1 mM sodium orthovanadate. Homogenate was spun at 100,000× g for 2 h to remove unsolubilized material before application to the column. The column was then washed twice in equilibration buffer, and bound protein was eluted with 4% pentadecafluorooctanoic acid in 100 mM phosphate buffer, pH 4.0. 1-ml fractions were collected, and protein content was assayed by measuring absorbance at 280 nm. Fractions containing the highest levels of protein (18-22) were pooled and concentrated in an Amicon Centriprep 50 concentrator (Millipore Corporation, Bedford, MA). Following determination of protein concentration using a modified Lowry protocol, eluant from all three columns was subjected to SDS-polyacrylamide gel electrophoresis (4-12% Tris-glycine, NOVEX) and silver staining.

For Western blotting analysis, antibodies were diluted to the required working concentrations in blocking buffer (5% milk, 0.1% Tween 20 in PBS). For sequential probing of the same samples, membranes were stripped by washing in SDS-stripping buffer at 55-60 °C for 40 min. Blots were first re-blocked and re-probed with secondary antibody to confirm effective stripping, before incubation with the desired antibody.

MALDI-TOF Mass Spectrometry and Identification of ClC-2-interacting Protein-- Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry was performed by the Mass Spectrometry Laboratory at the Molecular Medicine Research Centre (University of Toronto). Briefly, the dominant protein band (100 kDa) eluted from the ClC-2 affinity column was excised from the silver-stained gel, washed twice with acetonitrile followed by 0.1 M ammonium bicarbonate, and digested with 6.25 ng of trypsin (Roche Molecular Biochemicals) in 4 mM CaCl2, 50 mM ammonium bicarbonate at 37 °C overnight. Tryptic peptides were extracted from the gel slice with two washes of 100 µl each of 0.1 M ammonium bicarbonate. Pooled peptides were acidified by addition of acetic acid to 1% and reverse phase extracted with a 1:1 suspension of C18 silica resin. Resin was washed with two 100-µl aliquots of 2% acetonitrile, 1% acetic acid, and peptides were eluted with 5 µl of 65% acetonitrile, 1% acetic acid. A MALDI-TOF peptide mass fingerprint was obtained with an Applied Biosystems Voyager DE STR instrument using alpha -cyano hydroxycinnamic acid as a matrix.

Co-immunoprecipitation-- Hippocampal slices (300-µm thickness) were prepared from adult male rats (Sprague-Dawley, 150-200 g; Charles River) as described previously (13). A crude membrane preparation was obtained from tissue homogenate (in PBS with protease inhibitors by centrifugation at 100,000 × g for 1 h following a 10-min low speed spin at 2,000 × g to pellet nuclei and unlysed cells. For co-immunoprecipitations, 500 µg of protein from crude membrane preparations were solubilized in modified RIPA buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.05% (w/v) SDS, 1% Triton X-100 with protease inhibitors) at 37 °C for 10 min. Samples were spun at 15,000 × g to sediment unsolubilized protein aggregates and incubated with ClC-2 antibody (2 µg/ml) for 16 h at 4 °C. The antibody-protein complexes were adsorbed from solution with protein A-Agarose beads (Roche Molecular Biochemicals). Proteins were eluted from beads with SDS loading buffer containing 63 mM Tris-Cl, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, and 25 mM dithiothreitol. Samples were reduced with 10 mM Tris (2-carboxyethyl) phosphine and analyzed for the presence of dynein and ClC-2.

Cell Surface Biotinylation-- COS7 fibroblasts grown to 70% confluency on 15-cm dishes were incubated on ice for 30 min. Cells were washed with biotinylation buffer (1 mM MgCl2, 1 mM CaCl2, pH 7.8) and then incubated with 1.0 mg/ml sulfosuccinimidyl-2-(biotinamido) ethyl-1,3-dithiopropionate (Pierce) for 30 min on ice. Biotinylation was quenched by rinsing cells with 1% bovine serum albumin in PBS. Cells were then lysed with modified RIPA buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% (w/v) SDS, 1% Triton X-100 with protease inhibitors). Solubilized cell extracts were collected by centrifugation at 15,000 × g for 10 min. Supernatants were incubated with streptavidin beads (Pierce) for 1 h at 4 °C, and biotinylated proteins were eluted from beads with 63 mM Tris-Cl, pH 6.8, 10% (v/v) glycerol, 0.5 mM EDTA, 2% (w/v) SDS, 2% beta -mercaptoethanol, and 50 mM dithiothreitol. Eluants were then analyzed for the presence of ClC-2.

Patch Clamp Studies of COS7 Cells-- COS7 membrane currents were measured using conventional whole cell patch clamp technique as described previously (10). Briefly, currents were measured using an Axopatch 200A patch clamp amplifier (Axon Instruments, Foster City, CA) and were filtered at 100 Hz with a six-pore Bessel Filter. Sampling rate was 4 kHz for most data, and junction potentials were corrected. Voltage clamp protocols were generated using pCLAMP software (version 7; Axon Instruments). Current-voltage relationships were determined in a stepwise clamp protocol. From a holding potential of 30 mV, voltage pulses of 3.0 s were applied from -140 to +40 mV in 20-mV increments. The bath solution contained 140 mM N-methyl-D-glutamine chloride, 2 mM MgCl2, 2 mM CaCl2, 5 mM HEPES, whereas the pipette solution contained 140 mM N-methyl-D-glutamine chloride, 2 mM MgCl2, 2 mM EGTA, and 5 mM HEPES. Both pipette and bath solutions were adjusted to pH 7.4 and 260 milliosmoles.

Statistics-- Patch clamp and immunofluorescence quantitation data are presented as the means ± S.E. Most statistical analyses were performed using the Student's unpaired t test. Results obtained in patch clamp studies with drug-treated and -transfected cells were analyzed using the unpaired Student's t test. Differences between multiple treatment groups were assessed by ANOVA, and differences between specific pairs were subsequently analyzed using the Bonferroni method.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

ClC-2 Interacts with Rat Brain Dynein in in Vitro Studies-- As previous studies by Bali et al. (12) implicate a role for vesicular trafficking in ClC-2 regulation, we sought to identify proteins that may interact with ClC-2 and serve to mediate or regulate its translocation between the plasma membrane and intracellular vesicles. An affinity column bearing purified intact ClC-2 protein was used to capture ClC-2-binding proteins. Recombinant rat ClC-2 protein, engineered to possess a polyhistidine tail at its N terminus, was expressed in Sf9 cells using the baculovirus expression system and purified by metal affinity using the methods described in our previously published work (14). Purified ClC-2 was conjugated to a Hi-Trap column, through which mouse brain homogenate was passed. Brain tissue was used as starting material as ClC-2 is abundantly expressed in this organ (Fig. 1A). Control experiments were conducted simultaneously using an unconjugated and an amylase-conjugated Hi-Trap column. Interacting proteins were eluted using a pH gradient, and fractions containing the highest levels of protein were pooled, concentrated, and analyzed by SDS-PAGE and silver staining. Multiple silver-stained bands were detected specifically in the eluant from the ClC-2 affinity column (Fig. 1B). We excised the prominent 100-kDa band for analysis by mass spectrometry. Briefly, a MALDI-TOF peptide mass fingerprint of the excised band was obtained, and monoisotopic protonated peptide masses were used to search the NCBI sequence databases using PROFOUND. The tentative protein identification as a fragment of DHC subunit was based on the high number of matched peptide masses observed (25% sequence coverage) and low mass error (<0.5 atomic mass unit).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   ClC-2 interacts with the dynein motor complex in vitro. A, ClC-2 expression in murine hippocampus. Western blotting reveals a dominant band at 97 kDa, which is abolished upon pre-incubation of the ClC-2 antibody with antigenic peptide (+). Lanes were probed for actin to assess equal loading. B, eluted proteins from columns to which purified ClC-2, amylase, or nothing was conjugated were subjected to silver stain analysis. The major protein band (100 kDa) specific to the ClC-2 eluant was excised and identified by MALDI-TOF mass spectrometry to be a fragment of DHC. C, Western blotting analysis confirms the presence of DIC (a single 75-80-kDa band, also seen in whole brain homogenate; see Fig. 2B) in ClC-2 column eluant but not the amylase-conjugated column eluant.

The dynein motor complex is comprised of several different polypeptide components; a functional complex is typically composed of two copies of one of the heavy chain subunits, together with multiple copies of intermediate, light intermediate, and light chains (15). Dissociated heavy chain (isolated from purified bovine brain cytoplasmic dynein) migrates with an apparent molecular mass slightly greater than 200 kDa (15). As shown in Fig. 1B, silver stain analysis of the ClC-2 column eluant detects a similarly sized protein. However, commercially available antibodies were not effective in detecting the putative DHC fragment in total brain lysate or in immunoblots of the eluant from the ClC-2 affinity, possibly because of digestion of the antibody epitope. Recent experiments conducted by King et al. (15) report unstable DHC-containing subcomplexes generated from potassium iodide-treated purified bovine dynein, which was attributed to a loss in stability conferred by interactions with DIC and dynein light chain subunits. In fact, SDS-PAGE analysis of the DHC-containing complex revealed several distinct bands with molecular masses of slightly greater than 100 kDa (15). It is therefore possible that fragmentation of DHC may have occurred in our ClC-2 column because of a loss in stabilizing contacts with other dynein subunits during gradient pH elution. We reasoned that other subunits of the dynein motor complex may have been specifically eluted as multiple silver-stained bands were seen in Fig. 1B. Indeed, immunoblotting revealed the presence of DIC specifically in the ClC-2 column eluant (Fig. 1C). Furthermore, DIC migrates as a 75-80-kDa protein, and inspection of the silver-stained gel in Fig. 1B reveals the presence of a protein of this mass. These in vitro findings suggest that ClC-2 protein can interact (directly or indirectly) with the multi-subunit dynein motor complex.

ClC-2 Interacts with Dynein in in Vivo Studies-- To determine whether the interaction between ClC-2 and dynein exists in vivo, immunoprecipitation experiments were performed using rat hippocampal membranes and polyclonal antibodies directed against the N or the C terminus of ClC-2 or pre-immune IgG as a control. As with the N-terminal antibody (Nt-ClC-2; see Fig. 1A), the C-terminal-directed antibody (Ct-ClC-2) is specific as Western blotting of membranes prepared from murine brain tissue reveals a single band that migrates at 97 kDa that is absent in the ClC-2 knock-out sample (generated by Melvin and co-workers (4); see Fig. 2C). Crude hippocampal membranes were prepared, and immunoprecipitations were performed in the presence of 1% Triton X-100 plus 0.05% SDS as described under "Materials and Methods." Immunoprecipitates were subjected to SDS-PAGE and probed using our ClC-2 antibody directed against the N terminus. Similar levels of ClC-2 can be immunoprecipitated with both anti-ClC-2 antibodies (Fig. 2A). As expected, the nonspecific antibody (i.e. preimmune IgG) did not immunoprecipitate ClC-2. Co-precipitation of dynein with ClC-2 was assessed by probing the immunoprecipitates described above with anti-dynein (IC) antibody. Dynein IC could be detected in immunoprecipitates using our Ct-ClC-2 but not in immunoprecipitates using nonspecific IgG (n = 3) or our Nt-ClC-2 (n = 1) (Fig. 2B). These findings suggest that the ClC-2 interacts with the dynein motor protein complex in vivo and implicate the N terminus of ClC-2 in mediating this interaction.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Co-immunoprecipitation of dynein intermediate chain with ClC-2. A, samples containing either 500 µg (+) or 0 µg (-) of detergent-solubilized hippocampal membrane protein were incubated with anti-N-ClC-2, anti-C-ClC-2, or a nonspecific IgG as control. Precipitated protein-antibody complexes (+) or antibodies alone (-) were subjected to SDS-gel electrophoresis and probed for ClC-2 using our anti-Nt-ClC-2 antibody. B, protein/antibody complexes as described above were analyzed for the presence of DIC. DIC can be pulled down using anti-C-ClC-2 but not anti-N-ClC-2, implicating the N terminus of ClC-2 in mediating its interaction with dynein. C, specificity of our polyclonal C-terminal-directed ClC-2 antibody. Wild-type (+/+) and ClC-2 knock-out (-/-) mice brain tissue membranes (4) were probed with anti-Ct-ClC-2. Blots were also probed with anti-actin to assess equal protein loading.

ClC-2 Is Functionally Expressed at the Plasma Membrane of COS7 Cells-- The biochemical assays described in the preceding sections suggest an interaction between ClC-2 and the dynein motor complex. In the following studies, we assessed the functional significance of this interaction in the COS7 fibroblasts as this cell line endogenously expresses ClC-2 and can be readily transfected. Confocal micrographs of ClC-2-specific immunofluorescence in COS7 cells revealed a predominant perinuclear staining pattern with a fainter signal detected close to the cell surface (Fig. 3A, indicated by arrowheads). Electron micrographs of immunogold-labeled ClC-2 support our claim that ClC-2 localizes to the plasma membrane of COS7 cells (Fig. 3B). Further confirmation of the presence of ClC-2 at the cell surface was achieved using cell surface biotinylation. Intact COS7 fibroblasts were incubated with sulfosuccinimidyl-2-(biotinamido) ethyl-1,3-dithiopropionate to selectively label cell surface-associated proteins. To ensure that biotin had not labeled intracellular protein, we also assessed biotinylation of the abundant intracellular protein, actin. As shown in Fig. 3D, Western blotting analysis of biotinylated proteins isolated from COS7 extracts shows the presence of ClC-2 and the absence of actin. Hence, this biochemical assay reports cell surface incorporation of ClC-2 endogenously expressed in COS7 cells.


View larger version (87K):
[in this window]
[in a new window]
 
Fig. 3.   ClC-2 is functionally expressed at the cell surface of COS7 fibroblasts. A, immunofluorescence and confocal microscopy reveal a prominent ClC-2 perinuclear staining pattern, with detectable levels of protein at the cell surface. Unless otherwise indicated, scale bar represents 10 µm. B, immunogold electron microscopy confirms the surface localization of ClC-2. Control panel (C) shows no signal in the absence of primary antibody. Scale bar represents 100 nm. D, COS7 cells were surface-biotinylated (+) at 4 °C. Control experiments were conducted simultaneously where COS7 cells were incubated with buffer alone, without added biotinylation reagent (-). Western blotting analysis of biotinylated proteins confirms the presence of ClC-2. Intracellular actin could not be detected in the eluant. E, whole cell currents obtained by voltage steps of 20-mV increments, applied from -140 to 40 mV in control, untransfected (upper trace), and in antisense-transfected cells. F, mean I-V curves of ClC-2-mediated currents in untransfected and antisense transfected cells. The amplitude of ClC-2 currents is dramatically reduced when the cells are transfected with antisense ClC-2 cDNA. Error bars indicate S.E.

Whole cell patch clamp studies confirmed the functional expression of ClC-2 at the cell surface. Currents typical of those conferred by ClC-2 expression, with activation at hyperpolarizing voltage steps of at least -60 mV and greater, and an inwardly rectifying current-voltage relationship was detected (Fig. 3E). The observed current density had a magnitude of -21.5 ± 1.3 pA/pF (mean ± S.E., n = 10) at a membrane potential of -140 mV. To ensure that these measured currents were in fact mediated by ClC-2, we employed an antisense strategy. We have previously used this approach to confirm the functional expression of endogenous ClC-2 in Caco-2 cells (10), as there are no known specific blockers of the ClC-2-mediated chloride conductance (16). In this previous study, we showed that antisense ClC-2 cDNA significantly suppressed ClC-2 protein expression and reduced hyperpolarization-activated currents. This effect was specific, as an endogenous depolarization-activated chloride conductance was unaffected by antisense ClC-2 cDNA transfection (10). As in our previous studies in Caco-2 cells, we found that antisense ClC-2 cDNA transfection of COS7 cells led to significant suppression of endogenous hyperpolarization-activated chloride currents (Fig. 3, E and F). We observed a dramatic reduction in the magnitude of hyperpolarization-activated current densities (at -140 mV) in antisense-transfected cells (Fig. 3E; -7.2 ± 0.6 pA/pF, n = 10) relative to control (-21.5 ± 1.3 pA/pF; see Fig. 3F, n = 10; p < 0.0001). The abolition of hyperpolarization-activated chloride currents upon ClC-2 antisense (aClC-2) transfection demonstrates that ClC-2 channels are functionally expressed in the cell surface of COS7 cells. Furthermore, as in the previous Caco-2 cell studies (10), antisense ClC-2 cDNA had no effect on endogenous depolarization-activated chloride currents (at +40 mV, 2.6 ± 0.1 pA/pF in control cells versus 2.0 ± 0.3 in antisense-transfected cells, n = 10; p > 0.1) arguing that the effect was specific. Therefore, ClC-2 channels are expressed in the plasma membrane of COS7 cells, and hence, this cell line is suitable for studies of vesicular trafficking to and from the plasma membrane.

The Retrograde Trafficking of ClC-2 May Involve the Endosomal Pathway-- To determine whether ClC-2 is trafficked via endosomes in COS7 cells, we examined the relative localization of ClC-2 with respect to a marker of early endosomal vesicles; EEA1 (Fig. 4, A-C) using confocal microscopy. We found that the pattern of ClC-2-specific staining in COS7 cells at 37 °C showed no appreciable steady-state co-localization with EEA1 in COS7 cells, shown in Fig. 4A (merged image). However, as ClC-2 channels may associate with this compartment only transiently, we imposed a temperature block, i.e. 20 °C for 2 h, a maneuver known to be permissive to internalization but restrictive to trafficking out of early endosomes. This treatment has been shown to result in the formation of swollen early endosomes (17, 18). When COS7 cells were analyzed immediately following the 20 °C incubation, ClC-2-specific immunofluorescence retained a perinuclear staining pattern but also acquired the appearance of swollen vesicular structures, which partially overlapped with EEA1-specific immunofluorescence (Fig. 4B). Co-localization of ClC-2 in EEA1-positive compartments was most clearly evident in cells at 20 °C, which had been treated previously with cycloheximide to minimize protein expression in the biosynthetic pathway (Fig. 4C).


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 4.   A sub-population of intracellular ClC-2 localizes to early endosomes. A, minimal co-localization of ClC-2 with EEA1 in COS7 cells at 37 °C increases significantly upon incubation at 20 °C (B). C, accumulation of steady state levels of stable ClC-2 in early endosomes in cycloheximide-treated (CHX) cells. Scale bar represents 10 µm. D, quantitative analysis of ClC-2/EEA1 co-localization. A statistically significant increase in ClC-2 co-localization with EEA1 (*, p < 0.0001) was observed under both conditions. E, 20 °C temperature block causes a significant decrease in ClC-2 biotinylated at the cell surface (*, n = 3) reflecting endosomal sequestration.

Quantitative analysis of the percentage of overlapping ClC-2-specific and EEA1-specific immunofluorescence relative to total ClC-2-specific immunofluorescence was performed to provide a quantitative assessment of protein co-localization under different experimental conditions. In total, 71 cells exposed to the 20 °C treatment and 16 cells exposed to 20 °C with cycloheximide were compared with 64 untreated cells. Under control conditions, only 8.9 ± 0.9% of ClC-2 signal was found to co-localize with EEA1. Temperature arrest of vesicular exit from endosomes resulted in a statistically significant increase (p < 0.0001) in ClC-2 co-localization with EEA1 signal in the presence and in the absence of cycloheximide (22.0 ± 4.1% and 39.8 ± 4.4% respectively; see Fig. 4D). These results suggest that ClC-2 undergoes trafficking via endosomes and is retained in early endosomal compartments at 20 °C.

We would expect that the 20 °C trafficking block would decrease ClC-2 expression on the cell surface, as this temperature is permissive to internalization but inhibitory to trafficking out of early endosomes via recycling endosomes (19). As is shown in Fig. 4E, the level of ClC-2 expressed at the cell surface (assessed by biotinylation band densitometry) decreased by almost 63% upon incubation at 20 °C (n = 3). Together with the observation of increased co-localization of ClC-2 with EEA1 in cycloheximide-treated cells, these results support the notion that ClC-2 undergoes retrograde trafficking between the plasma membrane and endosomes.

ClC-2 Subcellular Distribution in COS7 Cells Is Dependent on Microtubule Integrity and Motor Function of the Dynein Complex-- To determine whether our biochemical findings suggesting an in vivo interaction between ClC-2 and the dynein motor complex are physiologically significant, we assessed the effect of disrupting microtubules and dynein motor function on ClC-2 localization. We first compared the subcellular distribution of ClC-2 with that of dynein. As shown in Fig. 5B, dynein exhibited a perinuclear distribution similar to ClC-2 (Fig. 5A), with significant dynein-specific immunofluorescence close to the cell surface. At a higher magnification, co-localization of ClC-2 and dynein was observed in regions proximal to the plasma membrane (Fig. 5, A and B, insets; co-localization indicated by arrowheads). Co-localization of these two proteins at the plasma membrane was evident in electron micrographs of immunogold-labeled ClC-2 and dynein (Fig. 5C). ClC-2 and dynein were also found to co-localize on continuous intracellular membranes (data not shown). Collectively, these findings suggest a possible role for dynein in mediating retrograde ClC-2-trafficking.


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 5.   ClC-2 (A) and dynein (B) co-localize at the cell surface of COS7 fibroblasts. Scale bar represents 10 µm. C, confirmation of ClC-2 and dynein co-localization at the plasma membrane using immunogold electron microscopy. Ultrathin COS7 sections were sequentially labeled for ClC-2 and dynein. 10 nm gold label corresponds to ClC-2 (white arrowhead), whereas 5 nm label identifies the dynein motor complex (black). Scale bar represents 100 nm.

The microtubule-depolymerizing agent nocodazole has been reported to inhibit dynein-based motility (20). If the dynein motor complex participates in the regulation of ClC-2 localization we predict that nocodazole treatment would perturb the normal subcellular distribution of ClC-2. To test this prediction, COS7 cells were therefore subjected to a 30-min incubation in serum-free growth medium supplemented with either 35 µM nocodazole in dimethyl sulfoxide (Me2SO; final concentration 0.01%) (v/v) or 0.01% Me2SO as control (Fig. 6, B and A, respectively). Following immediate fixation, cells were then processed for immunofluorescence analysis and labeled for ClC-2 and tubulin. As shown in Fig. 6B, nocodazole appeared to cause a dispersion of ClC-2. This effect was reversible as we found that ClC-2 localization was restored upon removal of the drug from the culture medium (data not shown), also ruling out the possibility of cytotoxic effects of the drug (21). When COS7 cells were subjected to nocodazole treatment at a reduced temperature (4 °C) at which microtubule depolymerization is still observed, but protein trafficking is halted, ClC-2 distribution was found to be unaltered (data not shown).


View larger version (79K):
[in this window]
[in a new window]
 
Fig. 6.   ClC-2 localization in COS7 cells is microtubule- and dynein-dependent. A-C, effect of nocodazole on microtubule integrity and ClC-2 distribution in COS7 cells. Control and nocodazole-treated cells were labeled for ClC-2 (left) and tubulin (right). In nocodazole-treated cells, ClC-2 loses its perinuclear staining pattern and is redistributed throughout the cytosol. C, line scanning analysis of ClC-2 signal in Me2SO- (white) and nocodazole-treated (black) cells. Error bars indicate S.E. D, early endosomal localization is disrupted upon dynamitin-GFP overexpression. Cells overexpressing dynamitin-GFP exhibit a fragmented and more dispersed distribution of EEA1-positive structures. E, transfected cells were also labeled for ClC-2 (left). ClC-2 displays a more dispersed distribution, extending throughout the cytosol and toward the edge of the cell (see arrowheads). F, line scanning analysis was conducted on 54 control (white) and 51 transfected cells (black). Differences between values obtained for untransfected cells versus transfected cells were statistically significant in all cases (p < 0.05).

We employed Image J software to quantify the relative effects of nocodazole or Me2SO (vehicle) on ClC-2 distribution. Line scan analysis was conducted on 36 drug-treated cells, and 32 Me2SO-control cells (randomly chosen from three independent trials). Mean values and their corresponding standard errors were calculated and plotted as bar graph representations using Origin software (Fig. 6C; black bars represent nocodazole-exposed cells), and unpaired Student's t tests were performed to determine whether any differences observed were statistically significant. Typically 55.3 ± 1.6% (mean ± S.E.) of endogenous ClC-2 fluorescence signal was within the first quarter length of the cell, with 27.8 ± 1.3%, 8.7 ± 0.7%, and 8.1 ± 0.6% in the second, third, and fourth quarter lengths, respectively. Microtubule disruption was found to shift ClC-2 fluorescence signal away from the perinuclear region toward the periphery of the cell. ClC-2 signal was distributed more evenly throughout the cytosol, so that less than half the original signal was in the first quarter length (26.0 ± 1.1%, p < 0.00001). A concomitant increase in fluorescence signal was seen in the peripheral quadrant, (21.7 ± 0.9% versus 8.1 ± 0.6%, p < 0.00001), supporting our visual impression that ClC-2 distribution is dependent on microtubule integrity. Collectively, these findings suggest that ClC-2 localization is regulated in part by a microtubule motor-dependent process.

As an alternative approach toward studying the role of dynein in ClC-2 trafficking, we investigated the effect of impaired dynein motor activity on ClC-2 localization. This was achieved by the overexpression of a dynactin subunit, dynamitin (22). Dynactin is believed to act as an intermediary or adaptor complex that facilitates dynein binding to its cargo (reviewed in Ref. 23). Overexpression of dynamitin results in the disruption of the dynactin complex by separating the p150glued subunit that interacts with dynein, from the Arp1 filament, which is thought to facilitate cargo/dynein protein interactions (24). The overexpression of dynamitin has been reported to disrupt dynein-dependent maintenance of membrane organelle distribution (22) and microtubule organization (25). The dynein-dynactin complex is also implicated in the movement of material within the endocytic pathway, as dynactin disruption by dynamitin overexpression was found to perturb endosomal trafficking (26). Similar effects can be seen by overexpressing the coiled-coil 1 domain of p150glued (CC1; amino acids 217-548), which binds dynein intermediate chain in vitro (27, 28) and is thus thought to be the dynein-binding domain of dynactin (25). To assess the effect of impaired dynein function on ClC-2 localization, we first tested the effectiveness of our system by labeling dynamitin-GFP-transfected COS7 cells with anti-EEA1 antibody. As expected on the basis of previous studies (22, 26), dynamitin-GFP-transfected cells were observed to have an altered EEA1 (early endosome) staining pattern (Fig. 6D, left panel). In contrast to its native compact juxtanuclear distribution, overexpression of dynamitin induced a redistribution of EEA1 into a more dispersed pattern, extending throughout the cytosol toward the periphery of the transfected cell (Fig. 6D, left panel; transfected cells indicated by GFP fluorescence, right panel). Similarly, ClC-2 distribution was disrupted in dynamitin overexpressing COS7 cells (Fig. 6E, left panel). ClC-2 lost its perinuclear localization and exhibited a more scattered distribution throughout the cytosol and toward the edge of the cell. We also observed a significant increase in ClC-2 localization at the plasma membrane in certain transfected cells (indicated by arrowheads; see Fig. 6E, left panel). Similar changes in ClC-2 distribution were seen upon transfection with the DSRedCC1 construct (data not shown), supporting the hypothesis that the dynein motor complex mediates trafficking of ClC-2 via the endosomal pathway.

Line scan analysis was performed to quantitatively assess the effect of dynamitin-GFP expression on ClC-2-specific immunofluorescence. 51 transfected cells (identified by GFP signal) and 54 untransfected cells were examined. The cells were randomly chosen from four independent transfections, and control cells were taken from transfected coverslips to minimize deviations in fluorescence signals attributed to experimental variation. Mean values and their corresponding standard errors were calculated and plotted as bar graph representations using Origin software (Fig. 6F; black bars represent transfected cells), and unpaired Student's t tests were performed to determine whether any differences observed were statistically significant. On average, 62.8 ± 1.5% (mean ± S.E.) of endogenous ClC-2 fluorescence signal was within the first quarter length, with 24.7 ± 1.3%, 9.1 ± 0.7%, and 5.9 ± 0.2% in the second, third, and fourth quarter lengths, respectively. As with the nocodazole treatment, overexpression of dynamitin-GFP was found to shift this distribution away from the perinuclear compartments, so that only 38.0 ± 0.7% signal was in the first quarter length (p < 0.00001). A statistically significant increase in fluorescence signal was seen in the remaining three quarter lengths (28.8 ± 0.6%, p < 0.05; 21.0 ± 0.7%, p < 0.00001; and 12.7 ± 0.5%, p < 0.00001), suggesting that the overexpression of dynamitin resulted in a redistribution of ClC-2 toward the periphery of the cell.

ClC-2 Functional Expression at the Cell Surface of COS7 Cells Is Dependent on Motor Function of the Dynein Complex-- The functional significance of disrupting ClC-2 localization by dynein inhibition was assessed in patch clamp studies. We measured the amplitude of hyperpolarization-activated currents in cells that were transfected with dynamitin-GFP. Consistent with our line scan analysis, we observed a significant increase in the amplitude of ClC-2-mediated current density in dynamitin-GFP-transfected cells (Fig. 7A, bottom trace). The current density measured at -140 mV increased 67%, from -21.5 ± 1.4 pA/pF (n = 10) to -35.9 ± 1.3 pA/pF (mean ± S.E., n = 14, p < 0.0001), suggesting that disruption of dynein function increases the number of ClC-2 channels in the plasma membrane (Fig. 7C). To ensure that the observed effect was specifically because of impaired dynein function at the level of vesicular trafficking and not because of impaired dynein biosynthesis, we assessed the effect of erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA), an inhibitor of the ATPase activity of the dynein complex (29, 30) (Fig. 7, B and D). Hyperpolarization-activated currents were recorded prior to and following treatment with 50 µM EHNA. ClC-2-mediated currents were typically recorded 10 min after addition of EHNA (Fig. 7A, middle trace). Multiple trials indicated a 2-fold increase in current density (-43.2 ± 2.3 pA/pF, n = 10, p < 0.0001) at -140 mV (Fig. 7B). These data are summarized in the bar graph shown in Fig. 7E. Identical experiments performed on Caco2 intestinal epithelial monolayers revealed an even greater increase in ClC-2 channel function at the plasma membrane upon dynein inhibition with EHNA (50 µM). Hyperpolarization-activated chloride currents mediated by ClC-2 increased from -23.9 ± 2.5 pA/pF to -69.9 ± 12.9 pA/pF (n = 7, p < 0.01; see Fig. 7D). Collectively, these findings are consistent with our hypothesis that dynein may be important in the vesicular transport of ClC-2.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   ClC-2-mediated chloride currents are activated by disruption of dynein function in COS7 and Caco2 cells. A, whole cell recordings for hyperpolarization-activated ClC-2 currents in control (untreated), EHNA-treated, and dynamitin-GFP-transfected cells. Mean I-V curves of ClC-2 currents in cells with normal dynein function (control, Con) and with impaired dynein function either by EHNA exposure (B) or dynamitin overexpression (C). D, EHNA also increases ClC-2-mediated currents on the cell surface of Caco2 cells. E, the effect of dynein inhibition by both EHNA treatment and dynamitin-GFP overexpression significantly increase ClC-2 currents at -140 mV (compared here with the effect of antisense-ClC-2 transfected cells). Error bars indicate S.E.

To determine whether the observed increase in ClC-2 channel function following disruption of dynein function is indicative of an increase in the amount of ClC-2 protein at the cell surface, we assessed the effect of EHNA on expression of ClC-2 in the plasma membrane by surface biotinylation. We assessed the effect of this pharmacological inhibitor of dynein function rather than the effect of dynamitin overexpression to optimize the number of affected cells and enhance the gain of our biochemical assay. Inhibition of dynein by the addition of EHNA was found to increase the amount of biotinylated ClC-2 by ~4-fold (Fig. 8). These findings suggest that the increase in hyperpolarization-activated currents caused by disruption of dynein function reflects an increase in the amount of ClC-2 at the cell surface.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 8.   EHNA inhibition of dynein results in an increase in ClC-2 protein at the cell surface. A, COS7 cells were exposed to either vehicle alone or 250 µM EHNA (0.025% Me2SO) for 20 min prior to cell surface biotinylation. B, band densitometry analysis shows a 4-fold increase (p < 0.0001) in the level of surface-associated ClC-2 in EHNA-treated cells in duplicate experiments. S.E. are indicated by error bars.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In the present report, we provide biochemical evidence for an in vitro and in vivo interaction between ClC-2 and dynein in brain tissue. First, we have shown that the dynein complex can interact with purified intact ClC-2 protein in our in vitro binding assay. This interaction likely also occurs in vivo, as dynein and ClC-2 can be co-immunoprecipitated from rat hippocampal slices. The functional consequences of this interaction were elucidated in the COS7 cell line using confocal microscopy and patch clamp electrophysiology. We demonstrate that dynein is important in ClC-2 trafficking, as disruption of dynein function not only causes dispersion of ClC-2 subcellular localization toward the plasma membrane but also increases ClC-2 expression and activity at the cell surface.

The molecular basis underlying the interaction between the dynein motor complex and ClC-2 remains to the determined. Hypothetically, the dynein motor complex may bind directly to ClC-2 as recent studies by Tai et al. (31) showed that the membrane protein, rhodopsin, can bind directly to the dynein light chain protein, Tctex. Interestingly, we could successfully co-immunoprecipitate dynein with ClC-2 using our C-terminal- but not our N-terminal-directed antibody. As both antibodies are effective in immunoprecipitating similar amounts of protein, this result possibly implicates the N terminus of ClC-2 in mediating its interaction with the dynein complex. The N terminus of ClC-2 has been implicated previously in the regulation of the channel function of the protein (32). However, our preliminary in vitro binding experiments (including GST-fusion pull-down and enzyme-linked immunosorbent assay assays) failed to provide evidence supporting a specific, direct interaction between purified dynein (kindly provided by S. King and T. Schroer) and GST-fusion proteins containing either the N terminus (residues 31-74) or C terminus (residues 869-907) of ClC-2. On the other hand, it is well known that dynactin interacts with and activates cytoplasmic dynein (33). Further, it has been shown that dynactin may recruit dynein to cargo in membrane vesicles directly (34) or indirectly via cytoskeletal proteins such as spectrin (35-37). Hence, in our future work, we will test the prediction that dynactin and spectrin may mediate the interaction between ClC-2 and dynein.

A role for the dynein motor complex in endocytosis has been implicated in previous studies. Burkhardt et al. (22) showed that disruption of the dynactin-dynein complex in COS7 cells by overexpression of dynamitin led to dispersion of endosomes toward the cell periphery. This observation was confirmed in the present work (Fig. 6D) and supports the putative role for this complex in retrograde endosomal trafficking (22, 26). Furthermore, cytoplasmic dynein has been shown to participate in phosphatidylinositol 3-kinase-regulated GLUT4 internalization in adipocytes (38). However, the present studies are the first to show that function of the dynein motor complex contributes to retrograde endosomal trafficking of an ion channel, thereby providing a novel molecular framework with which to study the regulated trafficking of ClC-2 channels and possibly other members of the ClC family of chloride channels. Two other members of this family, ClC-3 and ClC-5, have been localized to endosomal compartments (39-41). However, unlike ClC-2, which is thought to mediate its primary function at the cell surface, both ClC-3 and ClC-5 are stably expressed in endomembranes where they are thought to regulate the function of this organelle (39, 41). Hence, the molecular components mediating localization and trafficking of ClC-3 and ClC-5 may be distinct from those mediating ClC-2 trafficking.

In light of our current findings, we suggest that ClC-2 channel function at the cell surface can be regulated by modulation of vesicle retrieval from or insertion into the plasma membrane by dynein. In our future work, we plan to determine the role of dynein-mediated vesicular trafficking in ClC-2 activation by experimental maneuvers shown previously to regulate ClC-2 function at the cell surface. For example, activation of protein kinase C, cyclin-dependent kinase p34cdc2/cyclin B, and phosphatidylinositol 3-kinase have been shown to inhibit ClC-2 function at the cell surface (12, 32, 42, 43). Furthermore, Zheng et al. (43) showed that cyclin B-dependent phosphorylation of rabbit ClC-2 led to its enhanced ubiquitination and degradation. Finally, it will be important to determine how post-translational modification of ClC-2 regulates its interaction with molecular components within the ClC-2 trafficking pathway, such as the dynein motor complex.

    ACKNOWLEDGEMENTS

We are grateful to Professor T. Jentsch (Hamburg) for providing rClC-2 cDNA and Professor G. Cutting (The Johns Hopkins University) for providing hClC-2. We acknowledge Dr. Jeffrey Charuk (Mass Spectrometry Laboratory at the Molecular Medicine Research Centre, University of Toronto) for mass spectrometry analysis of the ClC-2 affinity column eluant. We are also grateful to Dr. Steven King (University of Connecticut) and Dr. Trina Schroer (The Johns Hopkins University) for providing us with purified bovine dynein and to Dr. Schroer for providing cDNA coding for dynamitin-GFP and dsRed-CC1. We also acknowledge Dr. Paul Park and Roberto Botelho for assistance with immunofluorescence image quantitation.

    FOOTNOTES

* This work was supported in part by a National Institutes of HealthGrant DK49096 (to C. E. B.) and by the Heart and Stroke Foundation of Canada.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by a studentship award from the Canadian Cystic Fibrosis Foundation.

** To whom correspondence should be addressed: Research Inst., Hospital for Sick Children, 555 University Ave., Toronto, Ontario M5G 1X8, Canada. Tel.: 416-813-5981; Fax: 416-813-5028; E-mail: bear@ sickkids.on.ca.

Published, JBC Papers in Press, February 23, 2003, DOI 10.1074/jbc.M209828200

    ABBREVIATIONS

The abbreviations used are: GFP, green fluorescent protein; IC, intermediate chain; DHC, dynein heavy chain; DIC, dynein IC; PBS, phosphate-buffered saline; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; EHNA, erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride; pA/pF, picoampere/picofarad.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Jentsch, T. J., Friedrich, T., Schriever, A., and Yamada, H. (1999) Pflugers Arch. 437, 783-795[CrossRef][Medline] [Order article via Infotrieve]
2. Thiemann, A., Grunder, S., Pusch, M., and Jentsch, T. J. (1992) Nature 356, 57-60[CrossRef][Medline] [Order article via Infotrieve]
3. Schwiebert, E. M., Cid-Soto, L. P., Stafford, D., Carter, M., Blaisdell, C. J., Zeitlin, P. L., Guggino, W. B., and Cutting, G. R. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3879-3884[Abstract/Free Full Text]
4. Nehrke, K., Arreola, J., Nguyen, H. V., Pilato, J., Richardson, L., Okunade, G., Baggs, R., Shull, G. E., and Melvin, J. E. (2002) J. Biol. Chem. 277, 23604-23611[Abstract/Free Full Text]
5. Rutledge, E., Bianchi, L., Christensen, M., Boehmer, C., Morrison, R., Broslat, A., Beld, A. M., George, A. L., Greenstein, D., and Strange, K. (2001) Curr. Biol. 11, 161-170[CrossRef][Medline] [Order article via Infotrieve]
6. Bosl, M. R., Stein, V., Hubner, C., Zdebik, A. A., Jordt, S. E., Mukhopadhyay, A. K., Davidoff, M. S., Holstein, A. F., and Jentsch, T. J. (2001) EMBO J. 20, 1289-1299[Abstract/Free Full Text]
7. Murray, C. B., Chu, S., and Zeitlin, P. L. (1996) Am. J. Physiol. 271, L829-L837[Medline] [Order article via Infotrieve]
8. Blaisdell, C. J., Pellettieri, J. P., Loughlin, C. E., Chu, S., and Zeitlin, P. L. (1999) Am. J. Respir. Cell Mol. Biol. 20, 842-847[Abstract/Free Full Text]
9. Gyomorey, K., Yeger, H., Ackerley, C., Garami, E., and Bear, C. E. (2000) Am. J. Physiol. Cell Physiol. 279, C1787-C1794[Abstract/Free Full Text]
10. Mohammad-Panah, R., Gyomorey, K., Rommens, J., Choudhury, M., Li, C., Wang, Y., and Bear, C. E. (2001) J. Biol. Chem. 276, 8306-8313[Abstract/Free Full Text]
11. Sik, A., Smith, R. L., and Freund, T. F. (2000) Neuroscience 101, 51-65[CrossRef][Medline] [Order article via Infotrieve]
12. Bali, M., Lipecka, J., Edelman, A., and Fritsch, J. (2001) Am. J. Physiol. Cell Physiol. 280, C1588-C1598[Abstract/Free Full Text]
13. Wan, Q., Man, H. Y., Braunton, J., Wang, W., Salter, M. W., Becker, L., and Wang, Y. T. (1997) J. Neurosci. 17, 5062-5069[Abstract/Free Full Text]
14. Ramjeesingh, M., Li, C., Huan, L. J., Garami, E., Wang, Y., and Bear, C. E. (2000) Biochemistry 39, 13838-13847[CrossRef][Medline] [Order article via Infotrieve]
15. King, S. J., Bonilla, M., Rodgers, M. E., and Schroer, T. A. (2002) Protein Sci. 11, 1239-1250[Abstract/Free Full Text]
16. Jentsch, T. J., Stein, V., Weinreich, F., and Zdebik, A. A. (2002) Physiol. Rev. 82, 503-568[Abstract/Free Full Text]
17. Dunn, W. A., Hubbard, A. L., and Aronson, N. N., Jr. (1980) J. Biol. Chem. 255, 5971-5978[Abstract/Free Full Text]
18. van Deurs, B., Petersen, O. W., Olsnes, S., and Sandvig, K. (1987) Exp. Cell Res. 171, 137-152[Medline] [Order article via Infotrieve]
19. Le, T. L., Yap, A. S., and Stow, J. L. (1999) J. Cell Biol. 146, 219-232[Abstract/Free Full Text]
20. Cole, N. B., Sciaky, N., Marotta, A., Song, J., and Lippincott-Schwartz, J. (1996) Mol. Biol. Cell 7, 631-650[Abstract]
21. Molero, J. C., Whitehead, J. P., Meerloo, T., and James, D. E. (2001) J. Biol. Chem. 276, 43829-43835[Abstract/Free Full Text]
22. Burkhardt, J. K., Echeverri, C. J., Nilsson, T., and Vallee, R. B. (1997) J. Cell Biol. 139, 469-484[Abstract/Free Full Text]
23. Schroer, T. A. (1994) Curr. Opin. Cell Biol. 6, 69-73[Medline] [Order article via Infotrieve]
24. Echeverri, C. J., Paschal, B. M., Vaughan, K. T., and Vallee, R. B. (1996) J. Cell Biol. 132, 617-633[Abstract]
25. Quintyne, N. J., Gill, S. R., Eckley, D. M., Crego, C. L., Compton, D. A., and Schroer, T. A. (1999) J. Cell Biol. 147, 321-334[Abstract/Free Full Text]
26. Valetti, C., Wetzel, D. M., Schrader, M., Hasbani, M. J., Gill, S. R., Kreis, T. E., and Schroer, T. A. (1999) Mol. Biol. Cell 10, 4107-4120[Abstract/Free Full Text]
27. Karki, S., and Holzbaur, E. L. (1995) J. Biol. Chem. 270, 28806-28811[Abstract/Free Full Text]
28. Vaughan, K. T., and Vallee, R. B. (1995) J. Cell Biol. 131, 1507-1516[Abstract]
29. Ekstrom, P., and Kanje, M. (1984) J. Neurochem. 43, 1342-1345[Medline] [Order article via Infotrieve]
30. Marples, D., Barber, B., and Taylor, A. (1996) J. Physiol. 490, 767-774[Abstract]
31. Tai, A. W., Chuang, J. Z., Bode, C., Wolfrum, U., and Sung, C. H. (1999) Cell 97, 877-887[Medline] [Order article via Infotrieve]
32. Grunder, S., Thiemann, A., Pusch, M., and Jentsch, T. J. (1992) Nature 360, 759-762[CrossRef][Medline] [Order article via Infotrieve]
33. King, S. J., and Schroer, T. A. (2000) Nat. Cell Biol. 2, 20-24[CrossRef][Medline] [Order article via Infotrieve]
34. Eckley, D. M., Gill, S. R., Melkonian, K. A., Bingham, J. B., Goodson, H. V., Heuser, J. E., and Schroer, T. A. (1999) J. Cell Biol. 147, 307-320[Abstract/Free Full Text]
35. Holleran, E. A., Tokito, M. K., Karki, S., and Holzbaur, E. L. (1996) J. Cell Biol. 135, 1815-1829[Abstract]
36. Holleran, E. A., Ligon, L. A., Tokito, M., Stankewich, M. C., Morrow, J. S., and Holzbaur, E. L. (2001) J. Biol. Chem. 276, 36598-36605[Abstract/Free Full Text]
37. Muresan, V., Stankewich, M. C., Steffen, W., Morrow, J. S., Holzbaur, E. L., and Schnapp, B. J. (2001) Mol. Cell 7, 173-183[Medline] [Order article via Infotrieve]
38. Huang, J., Imamura, T., and Olefsky, J. M. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13084-13089[Abstract/Free Full Text]
39. Gunther, W., Luchow, A., Cluzeaud, F., Vandewalle, A., and Jentsch, T. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8075-8080[Abstract/Free Full Text]
40. Piwon, N., Gunther, W., Schwake, M., Bosl, M. R., and Jentsch, T. J. (2000) Nature 408, 369-373[CrossRef][Medline] [Order article via Infotrieve]
41. Gentzsch, M., Cui, L., Mengos, A., Chang, X.-B., Chen, J.-H., and Riordan, J. R. (2003) J. Biol. Chem. 278, 6440-6449[Abstract/Free Full Text]
42. Fritsch, J., and Edelman, A. (1996) J. Physiol. 490, 115-128[Abstract]
43. Zheng, Y. J., Furukawa, T., Ogura, T., Tajimi, K., and Inagaki, N. (2002) J. Biol. Chem. 277, 32268-32273[Abstract/Free Full Text]
44. Janevski, J., Park, P. C., and De Boni, U. (1995) Exp. Cell Res. 217, 227-239[CrossRef][Medline] [Order article via Infotrieve]
45. Martou, G., and De Boni, U. (2000) Exp. Cell Res. 256, 131-139[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.